Bio-Techne Releases Fourth Quarter Fiscal 2026 Results

Bio-Techne posts stronger earnings as $11.3B Merck KGaA acquisition moves forward.

What the company is saying

Bio-Techne communicates two main messages: improved financial performance and the pending acquisition by Merck KGaA, Darmstadt, Germany. The announcement highlights a 3% organic revenue increase in the fourth quarter, a return to profitability with GAAP EPS rising to $0.35 from $(0.11), and a full-year GAAP EPS of $1.16 versus $0.46. The company emphasizes the $73 per share cash acquisition agreement, assigning it a total enterprise value of approximately $11.3 billion. The language is confident but measured, focusing on realised results and the definitive nature of the acquisition agreement. Forward-looking statements are limited to the expectation of closing the transaction and potential benefits for customers and employees. There is no attempt to overstate future synergies or growth, and the tone remains factual and direct.

What the data suggests

The numbers confirm a clear improvement in profitability: fourth quarter GAAP operating income swung from a $23.9 million loss last year to a $74.3 million profit, and GAAP EPS improved from $(0.11) to $0.35. Full-year GAAP EPS more than doubled to $1.16, while revenue held steady at $1.2 billion. Organic revenue growth was modest at 3% for the quarter, with only 1% reported growth, indicating some headwinds or currency effects. The acquisition price of $73 per share and $11.3 billion enterprise value are explicitly disclosed, providing clarity on the transaction terms. Disclosures are comprehensive for headline results but lack detail on cash flow, segment performance, or balance sheet strength. The data supports the company’s narrative of operational improvement and validates the acquisition’s valuation basis.

Analysis

The announcement is primarily factual, reporting realised financial results for the quarter and full year, including revenue, GAAP EPS, and operating income, all of which are supported by numerical evidence. The only forward-looking claim is related to the anticipated completion of the acquisition by Merck KGaA, which is already backed by a signed agreement, reducing execution risk. The tone is positive but proportionate to the disclosed improvements in profitability and the milestone of entering into a definitive acquisition agreement. The capital intensity flag is set to true due to the large $11.3 billion acquisition, but the risk is mitigated by the signed agreement. There is no narrative inflation or exaggerated language; all claims are either realised or directly supported by disclosed data.

Risk flags

• ●The acquisition is subject to closing conditions and potential regulatory approvals, which could delay or prevent completion. While the agreement is signed, external factors such as antitrust review or unforeseen legal challenges could still impact timing or outcome.
• ●Flat full-year revenue at $1.2 billion indicates limited top-line growth, suggesting that recent profitability improvements may not be sustainable without renewed revenue momentum. This stagnation could affect long-term value if not addressed post-acquisition.
• ●Disclosures omit cash flow and balance sheet data, making it difficult to assess underlying financial health or the company's ability to withstand operational shocks prior to deal close. Investors lack visibility into liquidity, leverage, or working capital trends.

Bottom line

Bio-Techne’s reported results show a marked turnaround in profitability, with GAAP EPS and operating income both improving sharply despite flat revenue. The $11.3 billion all-cash acquisition by Merck KGaA, at $73 per share, gives shareholders a clear exit path and sets a valuation floor. The company’s messaging is factual and avoids overpromising on post-acquisition benefits, with only standard forward-looking language about opportunities for stakeholders. The main risks are deal closure and the lack of detailed financial disclosures beyond headline numbers. For investors, the announcement is actionable: the acquisition price is explicit, and the likelihood of completion appears high given the signed agreement. The most important takeaway is that the investment thesis now centers on deal execution and timing, not ongoing operational performance.

Announcement summary

(NASDAQ: TECH) Bio-Techne Corporation reported its financial results for the fourth quarter ending June 30, 2026. Fourth quarter organic revenue increased by 3% (1% reported) to $321.2 million. Full year organic and reported revenue remained flat at $1.2 billion. GAAP EPS increased to $0.35 from $(0.11) one year ago, and full year GAAP EPS increased to $1.16 versus $0.46 one year ago. As previously announced on June 25, 2026, Bio-Techne entered into an agreement to be acquired by Merck KGaA, Darmstadt, Germany for $73 per share in cash, representing a total enterprise value of approximately $11.3 billion. GAAP operating income for the fourth quarter of fiscal 2026 was $74.3 million compared to an operating loss of $23.9 million in the fourth quarter of fiscal 2025. Bio-Techne operates in 34 locations worldwide and employs approximately 3,000 people.

Disagree with this article?